Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease

被引:61
|
作者
Lau, Dawn H. W. [1 ]
Hogseth, Marte [1 ]
Phillips, Emma C. [1 ]
O'Neill, Michael J. [2 ]
Pooler, Amy M. [1 ,3 ]
Noble, Wendy [1 ]
Hanger, Diane P. [1 ]
机构
[1] Kings Coll London, Dept Basic & Clin Neurosci, Maurice Wohl Clin Neurosci Inst K1 24, 125 Coldharbour Lane, London SE5 9NU, England
[2] Eli Lilly & Co Ltd, Lilly Res Ctr, Windlesham GU20 6PH, Surrey, England
[3] Nestle Inst Hlth Sci, Lausanne, Switzerland
来源
基金
英国生物技术与生命科学研究理事会;
关键词
Tau; Fyn; SH3; Alzheimer's disease; PXXP motif; Phosphorylation; ENDOGENOUS TAU; SH3; DOMAINS; PROTEIN-TAU; FAMILY; IDENTIFICATION; MICROTUBULES; AGGREGATION; INHIBITORS; SEQUENCE; KINASES;
D O I
10.1186/s40478-016-0317-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by neuropathological deposits of amyloid plaques and neurofibrillary tangles comprised of beta-amyloid and tau protein, respectively. In AD, tau becomes abnormally phosphorylated and aggregates to form intracellular deposits. However, the mechanisms by which tau exerts neurotoxicity in disease remain unclear. Recent studies have suggested that the presence of tau at synapses may indicate a role in neuronal signalling, which could be disrupted in pathological conditions. The non-receptor-associated tyrosine kinase fyn is located at the dendrite in neurons, where it was recently shown to interact with tau to stabilise receptor complexes at the post-synaptic density. Fyn also co-localises with tau in a proportion of neurons containing tau tangles in AD and fyn is also a tau kinase. Hence, tau-fyn interactions could play a pathogenic role in AD. Here we report the identification of critical proline residues, Pro213, Pro216, and Pro219, located within the fifth and sixth Pro-X-X-Pro motifs in the proline-rich region of tau, that are important for its binding to fyn. These residues in tau are flanked by numerous phosphorylation sites and therefore we investigated the relationship between fyn and the degree of tau phosphorylation in human post-mortem brain tissue. We found no difference in the amount of fyn present in control and AD brain. Notably, however, there was a significant correlation between fyn and phosphorylated tau at specific phospho-epitopes in control, but not in AD brain. Our results suggest that the pathological mechanisms underlying AD, that result in increased tau phosphorylation, may disrupt the physiological relationship between tau phosphorylation and fyn.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Tau-focused therapy and tau transmission: Implications for Alzheimer’s Disease and related tauopathies
    John Q Trojanowski
    Molecular Neurodegeneration, 8 (Suppl 1)
  • [32] Phosphorylation of different tau sites during progression of Alzheimer’s disease
    Joerg Neddens
    Magdalena Temmel
    Stefanie Flunkert
    Bianca Kerschbaumer
    Christina Hoeller
    Tina Loeffler
    Vera Niederkofler
    Guenther Daum
    Johannes Attems
    Birgit Hutter-Paier
    Acta Neuropathologica Communications, 6
  • [33] Tau protein and Alzheimer's disease: phosphorylation and role in intracellular traffic
    Mandelkow, E. M.
    Stamer, K.
    Vogel, R.
    Biernat, J.
    Mandelkow, E.
    JOURNAL OF ALZHEIMERS DISEASE, 2002, 4 (01) : 47 - 47
  • [34] Phosphorylation of different tau sites during progression of Alzheimer's disease
    Neddens, Joerg
    Temmel, Magdalena
    Flunkert, Stefanie
    Kerschbaumer, Bianca
    Hoeller, Christina
    Loeffler, Tina
    Niederkofler, Vera
    Daum, Guenther
    Attems, Johannes
    Hutter-Paier, Birgit
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2018, 6 : 52
  • [35] Phosphorylation of soluble tau differs in Pick’s disease and Alzheimer’s disease brains
    Janet van Eersel
    Mian Bi
    Yazi D. Ke
    John R. Hodges
    John H. Xuereb
    Gillian C. Gregory
    Glenda M. Halliday
    Jürgen Götz
    Jillian J. Kril
    Lars M. Ittner
    Journal of Neural Transmission, 2009, 116 : 1243 - 1251
  • [36] Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains
    van Eersel, Janet
    Bi, Mian
    Ke, Yazi D.
    Hodges, John R.
    Xuereb, John H.
    Gregory, Gillian C.
    Halliday, Glenda M.
    Goetz, Juergen
    Kril, Jillian J.
    Ittner, Lars M.
    JOURNAL OF NEURAL TRANSMISSION, 2009, 116 (10) : 1243 - 1251
  • [37] Molecular evolution of tau protein: Implications for Alzheimer's disease
    Nelson, PT
    Stefansson, K
    Gulcher, J
    Saper, CB
    JOURNAL OF NEUROCHEMISTRY, 1996, 67 (04) : 1622 - 1632
  • [38] miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer's disease
    Liu, Wei
    Zhao, Jingya
    Lu, Guangxiu
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 478 (02) : 852 - 857
  • [39] Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein
    Alonso, AD
    Zaidi, T
    Novak, M
    Barra, HS
    Grundke-Iqbal, I
    Iqbal, K
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (41) : 37967 - 37973
  • [40] Phosphorylation of tau antagonizes apoptosis by stabilizing β-catenin, a mechanism involved in Alzheimer's neurodegeneration
    Li, Hong-Lian
    Wang, Hai-Hong
    Liu, Shi-Jie
    Deng, Yan-Qiu
    Zhang, Yong-Jie
    Tian, Qing
    Wang, Xiao-Chuan
    Chen, Xiao-Qian
    Yang, Ying
    Zhang, Jia-Yu
    Wang, Qun
    Xu, Huaxi
    Liao, Francesca-Fang
    Wang, Jian-Zhi
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (09) : 3591 - 3596